Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report.

Pedersini R, Vattemi E, Lusso MR, Mazzoleni G, Ebner H, Graiff C.

Tumori. 2008 Nov-Dec;94(6):849-52.

PMID:
19267104
2.
3.

Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.

Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, Macciò A, Mantovani G.

Nutrition. 2006 Feb;22(2):136-45.

PMID:
16459226
5.

Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia.

Macciò A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G.

Blood. 2005 Jul 1;106(1):362-7. Epub 2005 Mar 17.

6.

Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.

Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R.

Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1651-9.

7.

Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity.

Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Gramignano G, Lusso MR, Curreli N, Rinaldi A.

J Exp Ther Oncol. 2004 Apr;4(1):69-78.

PMID:
15255293
8.

Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.

Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R.

J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19.

PMID:
14567291
9.

Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R.

J Mol Med (Berl). 2003 Oct;81(10):664-73. Epub 2003 Aug 19.

PMID:
12928788
10.

Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.

Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Madeddu C, Mura L, Mudu MC, Proto E, Tore G, Mura M, Macciò A, Ferreli A, Amichetti M.

Oncol Rep. 2003 May-Jun;10(3):759-66.

PMID:
12684655
11.

Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment.

Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L.

J Environ Pathol Toxicol Oncol. 2003;22(1):17-28.

PMID:
12678402
12.

The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E.

Free Radic Res. 2003 Feb;37(2):213-23.

PMID:
12653210
13.

Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment.

Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L.

J Cell Mol Med. 2002 Oct-Dec;6(4):570-82.

14.

Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.

Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A.

Oncol Rep. 2003 Jan-Feb;10(1):197-206.

PMID:
12469169
15.

Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.

Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L.

Oncol Rep. 2002 Jul-Aug;9(4):887-96.

PMID:
12066227
16.

Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Ferreli L, Contu P, Rinaldi A, Sanjust E, Atzei D, Elsener B.

Int J Cancer. 2002 Mar 1;98(1):84-91.

17.

Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.

Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L, Mudu MC, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Tore G, Mura M, Amichetti M, Maccio A.

Int J Oncol. 2002 Feb;20(2):419-27.

PMID:
11788911
18.

Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites.

Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Gramignano G, Piras MB.

J Mol Med (Berl). 2001 Jul;79(7):406-14.

PMID:
11466563
19.

Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites.

Mantovani G, Macciò A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu C, Dessì A.

J Mol Med (Berl). 2000;78(10):554-61.

PMID:
11199328
20.

Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.

Mantovani G, Maccio A, Madeddu C, Massa E, Mudu MC, Mulas C, Gramignano G, Massidda S, Murgia V, Lusso MR, Mura L.

Int J Oncol. 2001 Feb;18(2):383-91.

PMID:
11172608

Supplemental Content

Loading ...
Support Center